Core Viewpoint - Indaptus Therapeutics has entered into a $6 million securities purchase agreement with investor David E. Lazar, who has been appointed Co-CEO and Chairman of the Board, indicating a strategic move to enhance leadership and explore new opportunities for the company [1][2]. Investment Agreement - The agreement involves the issuance of 300,000 shares of non-voting convertible Series AA preferred stock and 700,000 shares of non-voting convertible Series AAA preferred stock in exchange for the $6 million investment [3]. - Each Series AA Preferred Stock share is convertible into 20 shares of common stock, while each Series AAA Preferred Stock share is convertible into 150 shares of common stock, pending stockholder approval expected in Q1 2026 [3]. Board Reconstitution - Following the agreement, the company's Board has been restructured, with David E. Lazar appointed as Chairman and Avraham Ben-Tzvi joining the Board, replacing Hila Kara and Dr. Robert Martell [4]. Company Overview - Indaptus Therapeutics focuses on innovative cancer and viral infection treatments, utilizing a Decoy platform that activates both innate and adaptive immune responses through a multi-targeted approach [6]. - The Decoy product candidates have shown promise in pre-clinical studies, demonstrating activity against various cancers and chronic viral infections, including chronic hepatitis B and HIV [6].